Association of {HER2} {ECD} and t-PSA serum levels for possible breast cancer diagnosis

摘要

Abstract Because of the high heterogeneity of breast cancer (BC), {BC} subtype-specific biomarker panel might be useful for diagnostic {BC} or becomes an adjunct assay to improve the accuracy of current screening methods. In this study, we measured the protein levels of human epidermal receptor-2 extracellular domain (HER2 ECD) and total prostate-specific antigen (t-PSA) in the serum from 14 {BC} patients and 8 healthy controls by utilizing our previously developed high-throughput metal-enhanced fluorescence biosensor. The experimental results showed that the summation of {HER2} {ECD} and t-PSA serum levels is proposed in this study. We found that {AUC} >0.9 of better ability to distinguish HER2+ group from HER2? and healthy groups. In the mean time, if taking the ratio of t-PSA and {HER2} {ECD} serum levels, it is very useful able to differentiate HER2? group from HER2+ and healthy groups at value of {AUC} >0.8. To our best knowledge, this is for the first time to integrate serum levels of {HER2} {ECD} and t-PSA levels potentially suggested in the screening {BC} patients for further improving the specificity by using our developed high-throughput metal-enhanced fluorescence biosensor.